Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

KIR2DS2 as predictor of thrombocytopenia secondary to pegylated interferon-alpha therapy

The Pharmacogenomics Journal volume 17, pages 360–365 (2017)Cite this article

Subjects

Abstract

Our aim was to evaluate the killer cell immunoglobulin-like receptors (KIRs) as a marker for the development of thrombocytopenia secondary to Peg-interferon (IFN) therapy in a cohort of human immunodeficiency virus (HIV)/hepatitis C virus (HCV) co-infected patients. Patients were naive to HCV treatment, receiving a first course of Peg-IFN/Ribavirin combination therapy. Total platelet count (cells ml–1) was determined at each visit, determining platelet decline from baseline to weeks 1, 2, 4, 8 and 12 after starting therapy. The end point of the study was development of thrombocytopenia, defined as a platelet count of <1 50 000 cells ml–1. Fifty-eight HIV/HCV co-infected patients were included in the study, of whom 20 (34.4%) developed thrombocytopenia. The absence of KIR2DS2 was associated with higher and faster rate of thrombocytopenia (54.2% vs 22.5%; P=0.012; 6.6 vs 10.3 weeks; P=0.008). The absence of KIR2DS2 was associated with a greater decline in platelet count and development of thrombocytopenia during Peg-IFN treatment in HIV/HCV co-infected patients.

Access through your institution
Buy or subscribe

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Platanias LC . Mechanisms of type-I and type-II-interferon mediated signalling. Nat Rev Immunol 2005; 5: 375–386.

    Article  CAS  Google Scholar 

  2. Lampertico P, Maini M, Papatheodoridis G . Optimal management of Hepatitis B virus infection- EASL Special conference. J Hepatol 2015; 63: 1238–1253.

    Article  Google Scholar 

  3. European Association for the Study of the Liver (EASL) Recommendations on Treatment of Hepatitis C 2014. Available at http://www.easl.eu/_newsroom/latest-news/easl-recommendations-on-treatment-of-hepatitis-c-2014 last accessed 1 October 2015.

  4. Recommendations for Testing, Managing, and Treating Hepatitis C of the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA). Available at http://www.hcvguidelines.org last accessed 1 October 2015.

  5. Peters van Ton AM, Gevers TJ, Drenth JP . Antiviral therapy in chronic hepatitis E: a systematic review. J Viral Hepat 2015; 22: 965–973.

    Article  CAS  Google Scholar 

  6. Ishitsuka K, Tamura K . Human T-cell leukaemia virus type I and adult T-cell leukaemia-lymphoma. Lancet Oncol 2014; 15: 517–526.

    Article  Google Scholar 

  7. Talpaz M, Mercer J, Hehlmann R . The interferon-alpha revival in CML. Ann Hematol 2015; 94: 195–207.

    Article  CAS  Google Scholar 

  8. Ludwig H, Durie BGM, McCarthy P, Palumbo A, San Miguel J, Morgan G et al. IMWG consensus on maintenance therapy in multiple myeloma. Blood 2012; 119: 3003–3015.

    Article  CAS  Google Scholar 

  9. Kaufman HL, Kirkwood JM, Hodi FS, Agarwala S, Amatruda T, Bines SD et al. The society for immunotherapy of cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol 2013; 10: 588–598.

    Article  CAS  Google Scholar 

  10. Gara N, Ghany MG . What the infectious disease physician needs to know about pegylated interferon and ribavirin. Clin Infect Dis 2013; 56: 1629–1636.

    Article  CAS  Google Scholar 

  11. Kowdley KV . Hematologic side effects of interferon and ribavirin therapy. J Clin Gastroenterol 2005; 39: 3–8.

    Article  Google Scholar 

  12. Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL et al. Innate or adaptative immunity? The example of natural killer cells. Science 2011; 331: 44–49.

    Article  CAS  Google Scholar 

  13. Shifrin N, Raulet DH, Ardolino M . NK cell self tolerance, responsiveness and missing self recognition. Semin Immunol 2014; 26: 138–144.

    Article  CAS  Google Scholar 

  14. Borrego F, Kabat J, Kim DK, Lieto L, Maasho K et al. Structure and function of major histocompatibility complex (MHC) class I specific receptors expressed on human natural killer (NK) cells. Mol Immunol 2002; 38: 637–660.

    Article  CAS  Google Scholar 

  15. Suppiah V, Gaudieri S, Armstrong NJ, O’Connor KS, Berg T et al. IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection. PLoS Med 2011; 8: e1001092.

    Article  CAS  Google Scholar 

  16. Rivero-Juarez A, Gonzalez R, Camacho A, Manzanares-Martin B, Caruz A, Martinez-Peinado A et al. Natural killer KIR3DS1 is closely associated with HCV viral clearance and sustained virological response in HIV/HCV patients. PLoS One 2013; 8: e61992.

    Article  CAS  Google Scholar 

  17. Vergara S, Macias J, Rivero A, Gutierrez-Valencia A, Gonzalez-Serrano M, Merino D et al. The use of transient elastmetry for assessing liver fibrosis in patients with HIV and hepatitis C virus coinfection. Clin Infect Dis 2007; 45: 969–974.

    Article  Google Scholar 

  18. Giannini EG . Review article: thrombocytopenia in chronic liver disease and pharmacologic treatment options. Aliment Pharmacol Ther 2006; 23: 1055–1065.

    Article  CAS  Google Scholar 

  19. Gomez-Lozano N, Vilches C . Genotyping of human killer-cell immunoglobulin-like receptor genes by polymerase chain reaction with sequence-specific primers: an update. Tissue Antigens 2002; 59: 184–193.

    Article  CAS  Google Scholar 

  20. Weksler BB . Review article: the pathophysiology of thrombocytopenia in hepatitis C virus infection and chronic liver disease. Aliment Pharmacol Ther 2007; 26: 13–19.

    Article  CAS  Google Scholar 

  21. Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S . Functions of natural killer cells. Nat Immunol 2008; 9: 503–510.

    Article  CAS  Google Scholar 

  22. Gorelik E, Bere WW, Herberman RB . Role of NK cells in the antimetastatic effect of anticoagulant drugs. Int J Cancer 1984; 33: 87–94.

    Article  CAS  Google Scholar 

  23. Nieswandt B, Hafner M, Echtenacher B, Mannel DN . Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res 1999; 59: 1295–1300.

    CAS  PubMed  Google Scholar 

  24. Palumbo JS, Talmage KE, Massari JV, La Jeunesse CM, Flick MJ, Kombrinck KW et al. Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood 2005; 105: 178–185.

    Article  CAS  Google Scholar 

  25. Li N . Platelet-lymphocyte cross-talk. J Leukoc Biol 2008; 83: 1069–1078.

    Article  CAS  Google Scholar 

  26. Semple JW, Freedman J . Platelets and innate immunity. Cell Mol Life Sci 2010; 67: 499–511.

    Article  CAS  Google Scholar 

  27. Seymour LA, Nourse JP, Crooks P, Wockner L, Bird R, Tran H et al. The presence of KIR2DS5 confers protection against adult immune thrombocytopenia. Tissue Antigens 2014; 83: 154–160.

    Article  CAS  Google Scholar 

  28. Nourse JP, Lea R, Crooks P, Wright G, Tran H, Catalano J et al. The KIR2DS2/2DL2 genotype is associated with adult persistent/chronic and relapsed immune thrombocytopenia independently of FCGR3a-158 polymorphisms. Blood Coagul Fibrinolysis 2012; 23: 45–50.

    Article  CAS  Google Scholar 

  29. Pradella P, Bonetto S, Turchetto S, Uxa L, Comar C, Zorat F et al. Platelet production and destruction in liver cirrhosis. J Hepatol 2011; 54: 894–900.

    Article  CAS  Google Scholar 

  30. Hernos JA, Quach L, Gagnon DR, Weber HC, Altincatal A, Cho K et al. Incident severe thrombocytopenia in veterans treated with pegylated interferon plus ribavirin for chronic hepatitis C infection. Pharmacoepidemiol Drug Saf 2014; 23: 480–488.

    Article  Google Scholar 

  31. Lin KH, Hsu PI, Yu HC, Lin CK, Tsai WL, Chen WC et al. Factors linked to severe thrombocytopenia during antiviral therapy in patients with chronic hepatitis C and pretreatment low platelet counts. BMC Gastroenterol 2012; 12: 7.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by the project RD12/0017, integrated in the Plan Nacional de I+D+I and cofinanced by the ISCIII-Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER). This works was also supported by Fundación Progreso y Salud de La Junta de Andalucía Project Grant (PI-0430/2012 and 0157/2011). AR-J is the recipient of a Post-Doctoral Research Extension Grant from the Fundación Progreso y Salud (Consejería de Salud, Innovación y Ciencia de la Junta de Andalucia). JAP has received a research extension grant from the Programa de Intensificación de la Actividad de Investigación del Servicio de Salud Carlos III (I3SNS).

Author contributions

AR and AR-J had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: AR-J, RG and AR. Analysis and interpretation of the data: AR-J, RG, BM-M and AR. Drafting of the manuscript: AR-J and AR. Critical revision of the manuscript for important intellectual content: all authors. Statistical analysis: AR-J. Obtained funding: AR-J and AR. Administrative, technical or material support: AR-J, RG, BM-M, MF, DR-C. Study supervision: AJ-R and AR.

Author information

Authors and Affiliations

  1. Infectious Diseases Unit, Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Hospital Universitario Reina Sofía de Córdoba, Universidad de Córdoba, Córdoba, Spain

    A Rivero-Juarez, M Frias, D Rodriguez-Cano, A Gordon, F Cuenca, A Camacho & A Rivero

  2. Immunology Unit, Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Hospital Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain

    R Gonzalez & B Manzanares-Martín

  3. Service de Medicina Tropical, Hospital de Poniente, El Ejido, Almería, Spain

    I Perez-Camacho

  4. Infectious Diseases and Clinical Microbiology Unit, Hospital Universitario de Valme, Seville, Spain

    J A Pineda

  5. Physiology and Immunology Department, Cellular Biology, Universidad de Córdoba, Córdoba, Spain

    J Peña

Authors
  1. A Rivero-Juarez
    View author publications

    Search author on:PubMed Google Scholar

  2. R Gonzalez
    View author publications

    Search author on:PubMed Google Scholar

  3. M Frias
    View author publications

    Search author on:PubMed Google Scholar

  4. B Manzanares-Martín
    View author publications

    Search author on:PubMed Google Scholar

  5. D Rodriguez-Cano
    View author publications

    Search author on:PubMed Google Scholar

  6. I Perez-Camacho
    View author publications

    Search author on:PubMed Google Scholar

  7. A Gordon
    View author publications

    Search author on:PubMed Google Scholar

  8. F Cuenca
    View author publications

    Search author on:PubMed Google Scholar

  9. A Camacho
    View author publications

    Search author on:PubMed Google Scholar

  10. J A Pineda
    View author publications

    Search author on:PubMed Google Scholar

  11. J Peña
    View author publications

    Search author on:PubMed Google Scholar

  12. A Rivero
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to A Rivero.

Ethics declarations

Competing interests

Neither the authors nor their institution received any payment or services from a third party for any aspect of the submitted work at any time (for example, data monitoring board, study design, manuscript preparation, statistical analysis). Outside the submitted work, AR and JAP have received consulting fees from Bristol-Myers Squibb, Abbott, Gilead, Roche, Boehringer Ingelheim, GlaxoSmithKline, Merck Sharp & Dohme, and Janssen-Cilag. He also has received lecture fees from GlaxoSmithKline, Roche, Abbott, Bristol-Myers Squibb, Boehringer Ingelheim and Schering-Plough. The remaining authors declare no conflict of interest.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rivero-Juarez, A., Gonzalez, R., Frias, M. et al. KIR2DS2 as predictor of thrombocytopenia secondary to pegylated interferon-alpha therapy. Pharmacogenomics J 17, 360–365 (2017). https://doi.org/10.1038/tpj.2016.19

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/tpj.2016.19

Search

Advanced search

Quick links